PMID- 19396032
OWN - NLM
STAT- MEDLINE
DCOM- 20090721
LR  - 20220224
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 15
IP  - 5
DP  - 2009 May
TI  - Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha 
      expression in pancreatic ductal adenocarcinoma: association with 
      clinicopathological parameters, tumor proliferative capacity, and patients' 
      survival.
PG  - BR148-56
AB  - BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a 
      ligand-activated transcription factor that forms heterodimers with the retinoid X 
      receptors (RXRs), is overexpressed in various tumors, regulating many aspects of 
      cancer biology. The aim of the present study was to evaluate the clinical 
      significance of PPAR-gamma and RXR-alpha expression in pancreatic adenocarcinoma. 
      MATERIAL/METHODS: PPAR-gamma and RXR-alpha protein expression was assessed 
      immunohistochemically in tumoral samples of 65 pancreatic adenocarcinoma patients 
      and statistically analyzed in relation to clinicopathological characteristics, 
      tumor proliferative capacity, and patients' survival. RESULTS: Of the 65 
      adenocarcinoma patients, 49 (75%) tested positive for PPAR-gamma and 55 (85%) 
      stained positive for RXR-alpha. RXR-alpha positivity was significantly associated 
      with tumor proliferative capacity and PPAR-gamma positivity (p=0.022 and p=0.043, 
      respectively). PPAR-gamma and RXR-alpha staining intensity were associated with 
      the histopathological tumor grade (p=0.003 and p=0.038, respectively). 
      Significant associations of PPAR-gamma staining intensity and RXR-alpha 
      expression with tumor size were also noted (p=0.041 and p=0.038, respectively). 
      Moderate and intense PPAR-gamma staining intensity was associated with shorter 
      overall survival in univariate analysis (log-rank test, p=0.023) and proved to be 
      an independent prognostic factor in multivariate analysis (p=0.045), whereas 
      RXR-alpha failed to predict patients' survival. CONCLUSIONS: These data revealed 
      that both PPAR-gamma and RXR-alpha were associated with pancreatic cancer 
      characteristics. PPAR-gamma, but not RXR-alpha, was found to be an independent 
      prognostic indicator. However, further molecular and clinical studies are 
      required to delineate the potential clinical application of PPAR-gamma and 
      RXR-alpha in the prognosis and management of pancreatic adenocarcinoma patients.
FAU - Giaginis, Constantinos
AU  - Giaginis C
AD  - Department of Forensic Medicine and Toxicology, University of Athens, Athens, 
      Greece.
FAU - Katsamangou, Eleftheria
AU  - Katsamangou E
FAU - Tsourouflis, Gerasimos
AU  - Tsourouflis G
FAU - Zizi-Serbetzoglou, Diamanto
AU  - Zizi-Serbetzoglou D
FAU - Kouraklis, Gregorios
AU  - Kouraklis G
FAU - Theocharis, Stamatios
AU  - Theocharis S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (PPAR gamma)
RN  - 0 (Retinoid X Receptors)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology
MH  - Aged
MH  - Carcinoma, Pancreatic Ductal/*metabolism/pathology
MH  - *Cell Proliferation
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - PPAR gamma/*metabolism
MH  - Pancreatic Neoplasms/*metabolism/pathology
MH  - Retinoid X Receptors/*metabolism
MH  - *Survival Analysis
EDAT- 2009/04/28 09:00
MHDA- 2009/07/22 09:00
CRDT- 2009/04/28 09:00
PHST- 2009/04/28 09:00 [entrez]
PHST- 2009/04/28 09:00 [pubmed]
PHST- 2009/07/22 09:00 [medline]
AID - 869638 [pii]
PST - ppublish
SO  - Med Sci Monit. 2009 May;15(5):BR148-56.